KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Assets Average: 2018-2025

Historic Assets Average for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $355.6 million.

  • Esperion Therapeutics' Assets Average rose 6.70% to $355.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.6 million, marking a year-over-year increase of 6.70%. This contributed to the annual value of $274.8 million for FY2024, which is 21.13% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Assets Average of $355.6 million as of Q3 2025, which was up 5.96% from $335.6 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Assets Average registered a high of $362.7 million during Q2 2024, and its lowest value of $213.6 million during Q4 2023.
  • Moreover, its 3-year median value for Assets Average was $329.0 million (2024), whereas its average is $297.6 million.
  • In the last 5 years, Esperion Therapeutics' Assets Average spiked by 60.34% in 2021 and then tumbled by 31.01% in 2023.
  • Esperion Therapeutics' Assets Average (Quarterly) stood at $303.4 million in 2021, then declined by 7.59% to $280.4 million in 2022, then decreased by 23.84% to $213.6 million in 2023, then surged by 54.05% to $329.0 million in 2024, then rose by 6.70% to $355.6 million in 2025.
  • Its Assets Average was $355.6 million in Q3 2025, compared to $335.6 million in Q2 2025 and $333.9 million in Q1 2025.